About this market
Availability of improved diagnostic modalities to drive growth in the market. To combat the shortcomings in the prognosis of pancreatic cancer, advanced diagnostic aids based on the principles of complementary DNA (cDNA) fingerprinting, PCR, and DNA microarray, and molecular profiling are being developed. The analysts have predicted that the pancreatic cancer therapeutics market will register a CAGR of more than 8% by 2023.
Market Overview
Robust pipeline and new drug approvals
The pipeline for the treatment of pancreatic cancer includes novel therapeutic approaches, including vaccines, gene therapy, stem cell therapy, and targeted therapy products.
High cost of treatments
Pancreatic cancer requires long term treatment, which increases the treatment cost and the economic burden on patients.
For the detailed list of factors that will drive and challenge the growth of the pancreatic cancer therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Pfizer and Shire the competitive environment is quite intense. Factors such as the robust pipeline and new drug approvals and the availability of improved diagnostic modalities, will provide considerable growth opportunities to pancreatic cancer therapeutics manufactures. Eli Lilly, F. Hoffmann-La Roche, Novartis, Pfizer, and Shire are some of the major companies covered in this report.